Market reactionShares rose 16% on Nov 4.
Viridian Therapeutics sells Lumvoa, an intravenous IGF-1R antibody approved for thyroid eye disease, and is preparing to file elegrobart, a subcutaneous IGF-1R antibody, for approval.
Viridian's case rests on thyroid eye disease. FDA approved Lumvoa, an IV IGF-1R antibody, on June 26, 2026, for active and chronic disease, and it launched immediately against Amgen's Tepezza. Elegrobart, a subcutaneous IGF-1R antibody, met its primary endpoints in REVEAL-1 and REVEAL-2, and a BLA is planned for the first quarter of 2027. Cash was $981.5 million at June 30, which Viridian expects to fund it through profitability.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Lumvoa gains share against Tepezza
Do Lumvoa's first full-quarter sales and payer coverage show real uptake against Tepezza?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Lumvoa launched in thyroid eye disease; the elegrobart BLA is planned for Q1 2027
Lumvoa approved and launched into a market Tepezza built; elegrobart's subcutaneous BLA is the next test of whether Viridian can take durable share
Veligrotug's June 2026 PDUFA decision will determine whether Viridian captures first-mover advantage in TED before Tepezza's competitive moat hardens further
Veligrotug's FDA PDUFA decision determines whether Viridian becomes the first IGF-1R antibody approved for both active and chronic TED
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Eye diseases, Autoimmune and inflammatory diseases, Endocrine and bone diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
4 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.